Objective To observe the expression of ezrin in prostate cancer tissues and explore the effect of ezrin gene silencing on the proliferation and invasion of human prostate cancer PC-3 cells and involved mechanisms. Methods The paraffin-embedded specimens of prostate cancer (n=20) and benign prostatic hyperplasia (n=20) were collected. Real-time quantitative PCR and Western blotting were used to detect the expression of ezrin mRNA and protein in prostate tissues, respectively. After culturing, human prostate cancer PC-3 cells were treated with culture solution, Scramble siRNA and ezrin siRNA for 48 hours. Cell proliferation was analyzed through MTT method. Cell invasion ability was measured using Transwell(TM) invasion experiment. In addition, the levels of E-cadherin and N-cadherin were examined by real-time quantitative PCR and Western blotting. Results The expression levels of ezrin mRNA and protein in prostate cancer tissues were higher than those in the tissues from benign prostatic hyperplasia patients. In comparison with PC-3 cells treated with Scramble siRNA, following the downregulation of ezrin expression, PC-3 cell proliferation was significantly inhibited and mean cell number of penetrated membrane and N-cadherin level were reduced, whereas E-cadherin level was raised. There was no statistical difference in the above indicators between Scramble siRNA-treated PC-3 cells and pure culture solution-treated PC-3 cells. Conclusion Ezrin is highly expressed in prostate cancer tissues. Gene silence of ezrin inhibits the proliferation and invasion of human prostate cancer PC-3 cells, meanwhile the level of E-cadherin is upregulated and N-cadherin is downregulated.
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology. 2016 Jun [Epub]
Ning Yang, Ling Wang, Xian Chen, Jun Liu, Zhigang Luo
Department of Urology, Second Affiliated Hospital, University of South China, Hengyang 421001, China., Hunan University of Environment and Biology, Hengyang 421001, China., Department of Urology, Second Affiliated Hospital, University of South China, Hengyang 421001, China., Department of Urology, Second Affiliated Hospital, University of South China, Hengyang 421001, China., Department of Urology, Second Affiliated Hospital, University of South China, Hengyang 421001, China. *Corresponding author, E-mail: .